Dudediligence.

Ginkgo Bioworks Holdings, Inc

DNANYSE · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$89.0MSep ’24$43.8MDec ’24$38.2MMar ’25$49.6MJun ’25$38.8MSep ’25$33.4MDec ’25$19.5MMar ’26$20.2MJun ’26
Net income, by quarter
−$56.4MSep ’24−$107.5MDec ’24−$91.0MMar ’25−$60.3MJun ’25−$80.8MSep ’25−$80.8MDec ’25−$82.6MMar ’26−$46.7MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$313.8M$477.7M$251.5M$227.0M$170.2M
Operating income−$1.83B−$2.21B−$864.4M−$559.8M−$315.3M
Net income−$1.83B−$2.10B−$892.9M−$547.0M−$312.8M
Operating cash flow−$253.8M−$252.2M−$295.5M−$319.6M−$171.1M
Free cash flow−$310.3M−$304.5M−$336.3M−$382.1M−$178.7M
Cash$1.55B$1.32B$944.1M$561.6M$167.2M
Shares outstanding1.61B1.89B50.0M54.4M58.2M